Adalimumab Dose Reduction and Withdrawal in Stable Non-Infectious Pediatric Uveitis: An Open-Label, Prospective, Pilot Study

References

• Rosenbaum JT, Dick AD. The eyes have it: a rheumatologist’s view of uveitis. Arthritis Rheumatol. 2018;70(10):1533–1543. doi:10.1002/art.40568.
   PubMed Web of Science ®Google Scholar
• Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol. 2003;135(5):676–680. doi:10.1016/S0002-9394(02)02148-7.
   PubMed Web of Science ®Google Scholar
• Holland GN, Stiehm ER. Special considerations in the evaluation and management of uveitis in children. Am J Ophthalmol. 2003;135(6):867–878. doi:10.1016/S0002-9394(03)00314-3.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852.
   PubMed Web of Science ®Google Scholar
• Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575–1581. doi:10.1016/j.ophtha.2012.02.018.
   PubMed Web of Science ®Google Scholar
• Horton S, Jones AP, Guly CM, Hardwick B, Beresford MW, Lee RW, et al. Adalimumab in juvenile idiopathic arthritis–associated uveitis: 5-year follow-up of the bristol participants of the SYCAMORE trial. Am J Ophthalmol. 2019;207:170–174. doi:10.1016/j.ajo.2019.06.007.
   PubMed Web of Science ®Google Scholar
• Muñoz-Gallego A, Barral E, Enríquez E, Tejada P, Barceló A, de Inocencio J. Adalimumab for the treatment of refractory noninfectious paediatric uveitis. Int Ophthalmol. 2017;37(3):719–725. doi:10.1007/s10792-016-0293-5.
   PubMed Web of Science ®Google Scholar
• Tanaka Y. Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis. Rheumatology (Oxford). 2016;55(suppl 2):ii15–ii22. doi:10.1093/rheumatology/kew352.
   PubMedGoogle Scholar
• Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. doi:10.1136/ard-2022-223356.
   PubMed Web of Science ®Google Scholar
• van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FHJ, Kievit W, van Vollenhoven RF, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ. 2015;350(apr09 23):h1389. doi:10.1136/bmj.h1389.
   PubMedGoogle Scholar
• Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, Beltrán E, Sánchez-Bursón J, Adán A, et al. Long-term follow-up and optimization of infliximab in refractory uveitis due to Behçet disease: national study of 103 white patients. J Rheumatol. 2021;48(5):741–750. doi:10.3899/jrheum.200300.
   PubMed Web of Science ®Google Scholar
• Martín-Varillas JL, Calvo-Río V, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, et al. Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s disease. Ophthalmology. 2018;125(9):1444–1451. doi:10.1016/j.ophtha.2018.02.020.
   PubMed Web of Science ®Google Scholar
• Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, et al. Key findings towards optimising adalimumab treatment: the concentration–effect curve. Ann Rheum Dis. 2015;74(3):513–518. doi:10.1136/annrheumdis-2013-204172.
   PubMed Web of Science ®Google Scholar
• van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69(3):624–625. doi:10.1136/ard.2009.108787.
   PubMed Web of Science ®Google Scholar
• Vogelzang E, Kneepkens E, Nurmohamed M, van Kuijk A, Rispens T, Wolbink G, et al. OP0074 OP0074 a concentration-effect curve of adalimumab in patients with psoriatic arthritis. Ann Rheum Dis. 2014;73(Suppl 2):88–89. doi:10.1136/annrheumdis-2014-eular.1863.
   Google Scholar
• Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016;25(3):1057–1073. doi:10.1177/0962280215588241.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan C-C, Roberge F. Standardizatlon of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi:10.1016/S0161-6420(85)34001-0.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–2285. doi:10.1001/jama.295.19.2275.
   PubMed Web of Science ®Google Scholar
• Etchevers MJ, Ordás I, Ricart E. Optimizing the use of tumour necrosis factor inhibitors in Crohn’s disease: a practical approach. Drugs. 2010;70(2):109–120. doi:10.2165/11533700-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Asahina A, Ohtsuki M, Etoh T, Gu Y, Okun MM, Teixeira HD, et al. Adalimumab treatment optimization for psoriasis: results of a long-term phase 2/3 Japanese study. J Dermatol. 2015;42(11):1042–1052. doi:10.1111/1346-8138.13001.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Smolen JS, Jones H, Szumski A, Marshall L, Emery P. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):164. doi:10.1186/s13075-019-1937-4.
   PubMed Web of Science ®Google Scholar
• Adán A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions. Int Ophthalmol. 2010;30(5):577–581. doi:10.1007/s10792-010-9372-1.
   PubMedGoogle Scholar
• Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282(1821):20143085. doi:10.1098/rspb.2014.3085.
   PubMed Web of Science ®Google Scholar
• Jani M, Chinoy H, Warren RB, Griffiths CEM, Plant D, Fu B, et al. Clinical utility of random anti–tumor necrosis factor drug–level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(8):2011–2019. doi:10.1002/art.39169.
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164–172. doi:10.1038/nrrheum.2013.4.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn’s disease. Aliment Pharmacol Ther. 2014;40(6):620–628. doi:10.1111/apt.12869.
   PubMed Web of Science ®Google Scholar
• Jani M, Chinoy H, Warren RB, Griffiths CEM, Plant D, Morgan AW, et al. Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet. 2015;385(Suppl 1):S48. doi:10.1016/S0140-6736(15)60363-4.
   PubMedGoogle Scholar
• Cordero-Coma M, Calleja-Antolín S, Garzo-García I, Nuñez-Garnés AM, Álvarez-Castro C, Franco-Benito M, et al. Adalimumab for treatment of noninfectious uveitis: immunogenicity and clinical relevance of measuring serum drug levels and antidrug antibodies. Ophthalmology. 2016;123(12):2618–2625. doi:10.1016/j.ophtha.2016.08.025.
   PubMed Web of Science ®Google Scholar
• Leinonen ST, Aalto K, Kotaniemi KM, Kivelä TT. Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis. Clin Exp Rheumatol. 2017;35:1043–1046.
   PubMed Web of Science ®Google Scholar